NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $4.99 payment

Ace your North American Pharmacist Licensure Examination (NAPLEX) with our comprehensive practice test. Features include interactive flashcards, multiple-choice questions, with detailed hints and explanations. Fast-track your pharmacy career today!

Practice this question and more.

What differentiates Rimegepant (Nurtec ODT) from Ubrogepant (Ubrelvy)?

Nurtec ODT is not approved for acute migraine attacks
Ubrelvy is also a CYP3A4 inducer
Nurtec is approved to prevent and treat acute migraine attacks
Ubrelvy can be used in children under 12

The correct answer is: Nurtec is approved to prevent and treat acute migraine attacks

Rimegepant (Nurtec ODT) and Ubrogepant (Ubrelvy) are both medications used for the treatment of migraines, specifically acute migraines. The main difference between the two lies in their approved indications. Rimegepant (Nurtec ODT) is unique because it is approved not only for the treatment of acute migraine attacks but also for the prevention of migraines, making it a versatile option for migraine management. On the other hand, Ubrogepant (Ubrelvy) is only approved for the treatment of acute migraine attacks, not for prevention. This distinction makes option C the correct answer. Options A, B, and D are incorrect: A. Nurtec ODT is actually approved for acute migraine attacks, so this statement is incorrect. B. Unlike Ubrogepant, Nurtec ODT is not a CYP3A4 inducer, making this statement incorrect. D. Ubrelvy is not approved for use in children under 12 years old, so this statement is incorrect.